Early PDE4 inhibitors have successfully been tested in animal models of experimental arthritis, autoimmune encephalomyelitis, and respiratory inflammatory diseases, where PDE4 inhibitors resulted in reduced inflammatory cell infiltrates and expression of pro-inflammatory cytokines [13], [30], [31]. Here, PDE4A is linked to arthritic joint disease.